The global market for mantle cell lymphoma treatment is poised for substantial growth, projected to reach US$ 2.53 billion in 2024 and expand at a CAGR of 8.6% from 2024 to 2034. This significant growth is fueled by advancements in targeted therapies, immunotherapy, personalized medicine, global market expansion, and the increasing incidence rates of mantle cell lymphoma (MCL) worldwide.
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma that affects the lymphatic system. The market is witnessing advancements in various treatment modalities, including immunotherapy, precision medicine, biomarker development, targeted therapies for specific pathways, combination therapies, and AI integration. These advancements are leading to more effective treatment options and improved patient outcomes.
The United States currently leads the global market, followed by Western Europe and East Asia. However, the South Asia & Pacific region is projected to experience the fastest growth rate over the next decade. Targeted therapy is the most widely used treatment approach globally.
Key takeaways from the market study include:
* The global market for mantle cell lymphoma treatment is expected to reach a value of US$ 5.77 billion by the end of 2034.
* The United States market is estimated to be worth US$ 899.1 million in 2024.
* India is projected to hold a significant market share of 63.8% in the South Asia & Pacific region by 2034.
* Revenue from targeted therapy is forecasted to reach US$ 2.09 million by the end of 2034.
* The East Asia market is anticipated to expand at a CAGR of 10.7% from 2024 to 2034.
The strong healthcare research infrastructure in the United States contributes significantly to its leading position in the global mantle cell lymphoma treatment market. The country’s ongoing innovation in therapeutic approaches, widespread access to cutting-edge medical technologies, and robust clinical trial activity drive its market dominance. The presence of world-renowned medical institutions, acclaimed oncologists, and collaborative efforts between academic and industrial sectors further solidify the United States’ leadership in developing effective treatments for mantle cell lymphoma.
The mantle cell lymphoma treatment market is also seeing significant developments in recent years:
* In March 2023, AstraZeneca’s Calquence (acalabrutinib), a next-generation selective BTK inhibitor, received provisional authorization in China for the treatment of adult patients with MCL who have undergone at least one prior therapy. This was the first approved indication for Calquence in China.
* In January 2023, the US Food and Drug Administration (FDA) approved Jaypirca, or pirtobrutinib, for the treatment of adult patients with relapsed or refractory MCL following at least two lines of systemic therapy, which included a BTK inhibitor.
The mantle cell lymphoma treatment market is segmented by therapy, drug, route of administration, end-user, and patient pool. The market is further categorized into seven major regions: North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA.
The global mantle cell lymphoma treatment market presents a promising outlook, driven by continued innovation, research, and development in the field. As new therapies emerge and treatment approaches evolve, the market is expected to witness significant growth in the coming years.
